Afya Limited (BVMF:A2FY34)
| Market Cap | 6.43B -35.7% |
| Revenue (ttm) | 3.77B +9.8% |
| Net Income | 757.48M +11.4% |
| EPS | 8.20 +9.2% |
| Shares Out | n/a |
| PE Ratio | 8.49 |
| Forward PE | 7.34 |
| Dividend | 1.64 (4.67%) |
| Ex-Dividend Date | Mar 24, 2026 |
| Volume | 2 |
| Open | 36.42 |
| Previous Close | 36.42 |
| Day's Range | 36.42 - 36.42 |
| 52-Week Range | 34.00 - 54.99 |
| Beta | 0.39 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Afya Limited
Afya Limited operates as a medical education group in Brazil. The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions. The Undergraduate segment offers educational services through undergraduate courses related to medical school, health sciences, and other non-health undergraduate programs, including medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine, business administration, accounting, law, civil and industrial engineering... [Read more]
Financial Performance
In 2025, Afya Limited's revenue was 3.70 billion, an increase of 11.89% compared to the previous year's 3.30 billion. Earnings were 752.46 million, an increase of 19.15%.
Financial StatementsNews
Afya Limited (the "Company") Notice of Annual General Meeting of the Company
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Notice is hereby given that an Annual General Meeting of the Company (the "AGM") will be held at the offices of Afya Participações S.A., Rua Paraíba, No. 330, ...
Afya Limited Announces First-Quarter 2026 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, repor...
Afya Limited Earnings Call Transcript: Q1 2026
Revenue rose 8% year-over-year to BRL 1.013 billion, with net income up 2% and strong cash flow. Growth was driven by higher medical course tickets, expanding health programs, and investments in digital solutions, despite margin pressure from increased costs.
Afya Limited Earnings release: Q1 2026
Afya Limited released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Afya Limited Slides: Q1 2026
Afya Limited has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Afya Limited Slides: Investor presentation
Afya Limited has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Moody's Reaffirmed Afya's AAA.br Rating With a Stable Outlook
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya price target lowered to $21.50 from $22 at JPMorgan
JPMorgan lowered the firm’s price target on Afya (AFYA) to $21.50 from $22 and keeps a Neutral rating on the shares. The firm updated the company’s estimates as part of…
Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, repor...
Afya Limited Announces Dividend Distribution of R$307.4 Million
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya Limited Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 12% revenue and 18% net income growth, robust cash flow, and a 19% EPS increase. 2026 guidance anticipates continued growth, with investments in technology and integration expected to impact margins.
Afya Limited Annual report: Q4 2025
Afya Limited has published its Q4 2025 annual report on March 12, 2026.
Afya Limited Earnings release: Q4 2025
Afya Limited released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Afya Limited Slides: Q4 2025
Afya Limited has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 12, 2026.
Afya downgraded to Neutral from Buy at BofA
BofA downgraded Afya (AFYA) to Neutral from Buy with a price target of $17, down from $22. The firm says the company’s rising investments in non-core businesses will pressure its…
Afya downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley downgraded Afya (AFYA) to Underweight from Equal Weight with a price target of $16, down from $17.50. The firm says that while the company’s medical undergrad operation remains…
Afya announces increased medical seats in Abaetetuba
Afya (AFYA) announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education has authorized an increase of 63 medical seats for Instituto Tocantinense Presid...
Afya Limited Announces Medical Seats Increase in Afya Abaetetuba
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and provider of medical practice solutions in Brazil, to...
Afya downgraded to Neutral from Buy at BTG Pactual
BTG Pactual downgraded Afya (AFYA) to Neutral from Buy with a $17 price target
Afya downgraded to Neutral from Buy at UBS
UBS downgraded Afya (AFYA) to Neutral from Buy with a price target of $16, down from $18. The firm says the company’s higher investments during a period of “naturally increased…
Afya price target lowered to $18 from $19 at UBS
UBS lowered the firm’s price target on Afya (AFYA) to $18 from $19 and keeps a Buy rating on the shares.
Afya downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Afya (AFYA) to Neutral from Overweight with a price target of $22, down from $24.50. The firm says the company benefits less from the easing cycle in Brazil…
Afya Announces Changes to Its Board of Directors
BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, annou...
Afya price target lowered to $22 from $25.50 at BofA
BofA lowered the firm’s price target on Afya (AFYA) to $22 from $25.50 and keeps a Buy rating on the shares after updating the firm’s estimates to incorporate a more…
Afya reports Q3 adjusted EBITDA R$398.9M, up 14.6% y/y
Reports Q3 revenue R$928.5M, or R$926.2M excluding acquisitions, vs. R$841.2M last year. Company management stated: “This quarter demonstrates once again Afya‘s (AFYA) ability to combine transformatio...